Ursodeoxycholic Acid (UDCA) exerts anti-Atherogenic effects by inhibiting RAGE signaling in diabetic atherosclerosis

PLoS ONE

Volumn 11, Issue 1, 2016, Pages 1-18

  Chung, Jihwa ^a   An, Shung Hyun ^a   Kang, Sang Won ^b   Kwon, Kihwan ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; URSODEOXYCHOLIC ACID;

ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIABETIC ANGIOPATHY; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; MOUSE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENDOPLASMIC RETICULUM STRESS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MICE; NF-KAPPA B; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; URSODEOXYCHOLIC ACID;

EID: 84958156551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147839     Document Type: Article

References (48)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999; 48(5):937-42. Epub 1999/05/20.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979; 241(19):2035-8. Epub 1979/05/11
3. Win MT, Yamamoto Y, Munesue S, Saito H, Han D, Motoyoshi S, et al. Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res. 2012; 2012:894605. Epub 2011/11/24. doi: 10.1155/2012/894605
4. Han SH, Kim YH, Mook-Jung I. RAGE: The beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells. 2011; 31(2):91-7. Epub 2011/02/25. doi: 10.1007/s10059-011-0030-x
5. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2008; 295(2):H491-8. Epub 2008/06/10. doi: 10.1152/ajpheart.00464.2008 00464.2008 [pii].
6. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012; 97(7):2231-42. Epub 2012/04/18. doi: 10.1210/jc. 2011-3408 jc.2011-3408 [pii].
7. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-Transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation. 2002; 105(7):816-22. Epub 2002/02/21.
8. Scull CM, Tabas I. Mechanisms of ER stress-induced apoptosis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31(12):2792-7. Epub 2011/11/19. doi: 10.1161/ATVBAHA.111.224881 31/12/2792 [pii].
9. Khan MI, Pichna BA, Shi Y, Bowes AJ, Werstuck GH. Evidence supporting a role for endoplasmic reticulum stress in the development of atherosclerosis in a hyperglycaemic mouse model. Antioxid Redox Signal. 2009; 11(9):2289-98. Epub 2009/06/25. doi: 10.1089/ARS.2009.2569
10. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr., Davies PF. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res. 2009; 105(5):453-61. doi: 10.1161/CIRCRESAHA.109.203711
11. Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res. 2010; 107(9):1071-82. Epub 2010/10/30. doi: 10.1161/CIRCRESAHA.110. 227819 107/9/1071 [pii].
12. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008; 454(7203):455-62. Epub 2008/07/25. doi: 10.1038/nature07203 nature07203 [pii].
13. Patel DC, Albrecht C, Pavitt D, Paul V, Pourreyron C, Newman SP, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One. 2011; 6(7):e22142. Epub 2011/08/11. doi: 10.1371/journal.pone.0022142 PONE-D-11-03999 [pii].
14. Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, et al. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J Biol Chem. 2006; 281(30):21216-Epub 2006/05/26. doi: M510952200 [pii] doi: 10.1074/jbc.M510952200
15. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology. 1998; 28(6):1449-53. Epub 1998/11/26. doi: S027091399800473X [pii] doi: 10.1002/hep.510280601
16. Cirillo NW, Zwas FR. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol. 1994; 89(9):1447-52. Epub 1994/09/01.
17. Ma J, Iida H, Jo T, Takano H, Oonuma H, Morita T, et al. Ursodeoxycholic acid inhibits endothelin-1 production in human vascular endothelial cells. Eur J Pharmacol. 2004; 505(1-3):67-74. Epub 2004/11/doi: S0014-2999(04)01227-0 [pii] doi: 10.1016/j.ejphar.2004.10.042
18. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006; 313(5790):1137-40. Epub 2006/08/26. doi: 313/5790/1137 [pii] doi: 10.1126/science.1128294
19. Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCalpha-mediated MKP-1 induction. Cardiovasc Res. 2011; 92(2):307-16. Epub 2011/08/16. doi: 10.1093/cvr/cvr219 cvr219 [pii].
20. Crampton SP, Davis J, Hughes CC. Isolation of human umbilical vein endothelial cells (HUVEC). Journal of visualized experiments: JoVE. 2007;(3: ):183. doi: 10.3791/183
21. Ha CH,WangW, Jhun BS,Wong C, Hausser A, Pfizenmaier K, et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factorinduced gene expression and angiogenesis. J Biol Chem. 2008; 283(21):14590-9. Epub 2008/03/12. doi: 10.1074/jbc.M800264200 M800264200 [pii]
22. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010; 59(1):249-55. Epub 2009/10/17. doi: 10.2337/db09-0801 db09-0801 [pii]
23. Ha CH, Kim S, Chung J, An SH, Kwon K. Extracorporeal shock wave stimulates expression of the angiogenic genes via mechanosensory complex in endothelial cells: Mimetic effect of fluid shear stress in endothelial cells. Int J Cardiol. 2013. Epub 2013/08/07. doi: S0167-5273(13)01323-5 [pii] doi: 10. 1016/j.ijcard.2013.07.112
24. Ha CH, Kim S, Chung J, An SH, Park S, Choi D, et al. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis. International journal of molecular medicine. 2013; 32(2):373-80. Epub 2013/05/28. doi: 10.3892/ijmm.2013.1393
25. Lee DJ, Kang DH, Choi M, Choi YJ, Lee JY, Park JH, et al. Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/beta-Catenin complexes in adherens junctions. Cancer Res. 2013; 73(15):4744-57. Epub 2013/06/12. doi: 10.1158/0008-5472.CAN-12-4226 0008-5472.CAN-12-4226 [pii].
26. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002; 106(22):2827-35. Epub 2002/11/
27. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004; 39(6):1563-73. Epub 2004/06/09. doi: 10.1002/hep.20246
28. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008; 57(9):2461-9. Epub 2008/05/31. doi: 10.2337/db07-1808 db07-1808 [pii]
29. Werstuck GH, Khan MI, Femia G, Kim AJ, Tedesco V, Trigatti B, et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes. 2006; 55(1):93-101. Epub 2005/12/29.
30. Zhou J, Lhotak S, Hilditch BA, Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 2005; 111 (14):1814-21. doi: 10.1161/01.CIR.0000160864.31351.C1
31. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl). 2009; 87(3):235-47. Epub 2009/02/04. doi: 10.1007/s00109-009-0439-2
32. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr., Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998; 4 (9):1025-31. Epub 1998/09/12. doi: 10.1038/2012
33. Urano F, Wang XZ, Bertolotti A, Zhang YH, Chung P, Harding HP, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000; 287 (5453):664-6. doi: 10.1126/science.287.5453.664 ISI:000084989400051.
34. Kaneko M, Niinuma Y, Nomura Y. Activation signal of nuclear factor-kappa B in response to endoplasmic reticulum stress is transduced via IRE1 and tumor necrosis factor receptor-Associated factor 2. Biol Pharm Bull. 2003; 26(7):931-5. Epub 2003/07/05.
35. Liu W, Schoenkerman A, Lowe WL Jr. Activation of members of the mitogen-Activated protein kinase family by glucose in endothelial cells. Am J Physiol Endocrinol Metab. 2000; 279(4):E782-90. Epub 2000/09/23.
36. McGinn S, Saad S, Poronnik P, Pollock CA. High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol Endocrinol Metab. 2003; 285(4):E708-17. Epub 2003/06/ doi: 10.1152/ajpendo.00572.2002
37. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-Terminal kinase and caspase-3. Circulation. 2000; 101(22):2618-24. Epub 2000/06/07.
38. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-Associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001; 50 (12):2792-808. Epub 2001/11/28.
39. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404 (6779):787-90. Epub 2000/04/28. doi: 10.1038/35008121
40. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Current neurovascular research. 2007; 4(1):63-71. Epub 2007/02/22
41. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes care. 2003; 26(5):1589-96. Epub 2003/04/30.
42. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-Activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine reviews. 2002; 23(5):599-622. Epub 2002/10/10. doi: 10.1210/er.2001-0039
43. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865):813-20. Epub 2001/12/14. doi: 10.1038/414813a
44. Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes. 2003; 52(3):621-33.
45. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: A vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007; 9(12):2277-93. doi: 10.1089/ars.2007.1782
46. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem. 2003; 278(10):8135-45. doi: 10.1074/jbc. M211898200
47. Kumar P, Raghavan S, Shanmugam G, Shanmugam N. Ligation of RAGE with ligand S100B attenuates ABCA1 expression in monocytes. Metabolism. 2013; 62(8):1149-58. Epub 2013/03/26. doi: 10. 1016/j.metabol.2013.02.006 S0026-0495(13)00053-X [pii].
48. Daffu G, Shen X, Senatus L, Thiagarajan D, Abedini A, Hurtado Del Pozo C, et al. RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes. Diabetes. 2015. doi: 10.2337/db15-0575